Kiora Pharmaceuticals Inc Asset Resilience Ratio
Kiora Pharmaceuticals Inc asset resilience ratio. Kiora Pharmaceuticals Inc (KPRX) has an Asset Resilience Ratio of 41.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kiora Pharmaceuticals Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kiora Pharmaceuticals Inc (2023–2025)
Asset resilience ratio of Kiora Pharmaceuticals Inc from 2023 to 2025. This chart shows how Kiora Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read KPRX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kiora Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Kiora Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.76 Million | 41.06% |
| Total Liquid Assets | $9.76 Million | 41.06% |
Asset Resilience Insights
- Very High Liquidity: Kiora Pharmaceuticals Inc maintains exceptional liquid asset reserves at 41.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kiora Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Kiora Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Kiora Pharmaceuticals Inc Asset Resilience Ratio by Year (2023–2025)
Kiora Pharmaceuticals Inc asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Kiora Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.60% | $8.39 Million | $24.25 Million | -28.44pp |
| 2024-12-31 | 63.04% | $23.00 Million | $36.48 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $13.71 Million | -- |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more